Eikon Therapeutics, Inc.
EIKN
$12.31
$0.786.77%
NASDAQ
| 12/31/2025 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | 27.43% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 22.41% | ||||
| Operating Income | -22.41% | ||||
| Income Before Tax | -22.69% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -22.69% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -22.69% | ||||
| EBIT | -22.41% | ||||
| EBITDA | -21.20% | ||||
| EPS Basic | -8.37% | ||||
| Normalized Basic EPS | -8.10% | ||||
| EPS Diluted | -8.37% | ||||
| Normalized Diluted EPS | -8.10% | ||||
| Average Basic Shares Outstanding | 13.21% | ||||
| Average Diluted Shares Outstanding | 13.21% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||